# Enovix Corp: financial statements, quarterly ENVX · Nasdaq · CIK 1828318 · [Technology](/sectors/technology.md) · fiscal year ends Dec 28 Pages: [Overview](/companies/envx.md) · [Financials](/companies/envx/financials.md) · [Filings](/companies/envx/filings.md) · [Insiders](/companies/envx/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/envx/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-28) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001828318-24-000233.md) | [7.4 d](/filings/0001828318-26-000006.md) | [5.3](/filings/0001828318-25-000148.md) | [3.8](/filings/0001828318-25-000275.md) | [4.3](/filings/0001828318-25-000310.md) | [9.7 d](/filings/0001828318-26-000006.md) | [5.1](/filings/0001828318-26-000029.md) | [7.5](/filings/0001828318-26-000056.md) | [8.0](/filings/0001828318-25-000310.md) | [11.3 d](/filings/0001828318-26-000006.md) | [7.6](/filings/0001828318-26-000029.md) | [9.0](/filings/0001828318-26-000056.md) | | Cost of revenue | $m | [16.8](/filings/0001828318-24-000233.md) | [19.8 d](/filings/0001828318-26-000006.md) | [7.1](/filings/0001828318-25-000148.md) | [4.4](/filings/0001828318-25-000275.md) | [5.0](/filings/0001828318-25-000310.md) | [8.7 d](/filings/0001828318-26-000006.md) | [4.8](/filings/0001828318-26-000029.md) | [5.5](/filings/0001828318-26-000056.md) | [6.6](/filings/0001828318-25-000310.md) | [8.8 d](/filings/0001828318-26-000006.md) | [6.0](/filings/0001828318-26-000029.md) | [7.7](/filings/0001828318-26-000056.md) | | Gross profit | $m | [(16.6)](/filings/0001828318-24-000233.md) | [(12.4) d](/filings/0001828318-26-000006.md) | [(1.8)](/filings/0001828318-25-000148.md) | [(0.7)](/filings/0001828318-25-000275.md) | [(0.6)](/filings/0001828318-25-000310.md) | [1.1 d](/filings/0001828318-26-000006.md) | [0.3](/filings/0001828318-26-000029.md) | [1.9](/filings/0001828318-26-000056.md) | [1.4](/filings/0001828318-25-000310.md) | [2.5 d](/filings/0001828318-26-000006.md) | [1.6](/filings/0001828318-26-000029.md) | [1.3](/filings/0001828318-26-000056.md) | | Research and development | $m | [13.5](/filings/0001828318-24-000233.md) | [34.6 d](/filings/0001828318-26-000006.md) | [48.8](/filings/0001828318-25-000148.md) | [29.1](/filings/0001828318-25-000275.md) | [24.2](/filings/0001828318-25-000310.md) | [22.4 d](/filings/0001828318-26-000006.md) | [25.9](/filings/0001828318-26-000029.md) | [28.1](/filings/0001828318-26-000056.md) | [28.2](/filings/0001828318-25-000310.md) | [28.1 d](/filings/0001828318-26-000006.md) | [26.5](/filings/0001828318-26-000029.md) | [24.4](/filings/0001828318-26-000056.md) | | Selling, general and administrative | $m | [17.2](/filings/0001828318-24-000233.md) | [17.8 d](/filings/0001828318-26-000006.md) | [19.5](/filings/0001828318-25-000148.md) | [20.9](/filings/0001828318-25-000275.md) | [20.7](/filings/0001828318-25-000310.md) | [13.1 d](/filings/0001828318-26-000006.md) | [16.9](/filings/0001828318-26-000029.md) | [17.5](/filings/0001828318-26-000056.md) | [20.2](/filings/0001828318-25-000310.md) | [18.4 d](/filings/0001828318-26-000006.md) | [18.9](/filings/0001828318-26-000029.md) | [20.2](/filings/0001828318-26-000056.md) | | Operating income | $m | [(50.4)](/filings/0001828318-24-000233.md) | [(64.8) d](/filings/0001828318-26-000006.md) | [(70.1)](/filings/0001828318-25-000148.md) | [(88.8)](/filings/0001828318-25-000275.md) | [(49.3)](/filings/0001828318-25-000310.md) | [(34.5) d](/filings/0001828318-26-000006.md) | [(42.6)](/filings/0001828318-26-000029.md) | [(43.7)](/filings/0001828318-26-000056.md) | [(47.0)](/filings/0001828318-25-000310.md) | [(44.0) d](/filings/0001828318-26-000006.md) | [(43.9)](/filings/0001828318-26-000029.md) | [(43.3)](/filings/0001828318-26-000056.md) | | Interest expense | $m | [1.6](/filings/0001828318-23-000206.md) | [1.6 d](/filings/0001828318-24-000021.md) | [1.7](/filings/0001828318-24-000066.md) | [1.7](/filings/0001828318-25-000275.md) | [1.7](/filings/0001828318-25-000310.md) | [1.7 d](/filings/0001828318-26-000006.md) | [1.7](/filings/0001828318-26-000029.md) | [1.7](/filings/0001828318-26-000056.md) | [11.8](/filings/0001828318-25-000310.md) | [6.4 d](/filings/0001828318-26-000006.md) | [7.0](/filings/0001828318-26-000029.md) | [6.5](/filings/0001828318-26-000056.md) | | Income tax | $m | [0.0](/filings/0001828318-24-000233.md) | [(0.6) d](/filings/0001828318-26-000006.md) | [(0.2)](/filings/0001828318-25-000148.md) | [(4.6)](/filings/0001828318-25-000275.md) | [2.2](/filings/0001828318-25-000310.md) | [1.2 d](/filings/0001828318-26-000006.md) | [(0.2)](/filings/0001828318-26-000029.md) | [(0.9)](/filings/0001828318-26-000056.md) | [(0.4)](/filings/0001828318-25-000310.md) | [0.1 d](/filings/0001828318-26-000006.md) | [(0.1)](/filings/0001828318-26-000029.md) | [(0.4)](/filings/0001828318-26-000056.md) | | Net income | $m | [(16.2)](/filings/0001828318-24-000233.md) | [(60.0) d](/filings/0001828318-26-000006.md) | [(46.4)](/filings/0001828318-25-000148.md) | [(116)](/filings/0001828318-25-000275.md) | [(22.5)](/filings/0001828318-25-000310.md) | [(37.5) d](/filings/0001828318-26-000006.md) | [(23.5)](/filings/0001828318-26-000029.md) | [(44.5)](/filings/0001828318-26-000056.md) | [(53.7)](/filings/0001828318-25-000310.md) | [(35.0) d](/filings/0001828318-26-000006.md) | [(38.3)](/filings/0001828318-26-000029.md) | [(43.1)](/filings/0001828318-26-000056.md) | | Diluted EPS | $ per share | [(0.29)](/filings/0001828318-24-000233.md) | not reported | [(0.28)](/filings/0001828318-25-000148.md) | [(0.63)](/filings/0001828318-25-000275.md) | [(0.28)](/filings/0001828318-25-000310.md) | not reported | [(0.12)](/filings/0001828318-26-000029.md) | [(0.22)](/filings/0001828318-26-000056.md) | [(0.27)](/filings/0001828318-25-000310.md) | not reported | [(0.18)](/filings/0001828318-26-000029.md) | [(0.20)](/filings/0001828318-26-000056.md) | | Basic EPS | $ per share | [(0.10)](/filings/0001828318-24-000233.md) | not reported | [(0.28)](/filings/0001828318-25-000148.md) | [(0.63)](/filings/0001828318-25-000275.md) | [(0.12)](/filings/0001828318-25-000310.md) | not reported | [(0.12)](/filings/0001828318-26-000029.md) | [(0.22)](/filings/0001828318-26-000056.md) | [(0.26)](/filings/0001828318-25-000310.md) | not reported | [(0.18)](/filings/0001828318-26-000029.md) | [(0.20)](/filings/0001828318-26-000056.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-10-01) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | FY2025 (2025-12-28) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [271](/filings/0001828318-24-000233.md) | [233](/filings/0001828318-26-000006.md) | [222](/filings/0001828318-25-000148.md) | [235](/filings/0001828318-25-000275.md) | [201](/filings/0001828318-25-000310.md) | [273](/filings/0001828318-26-000006.md) | [190](/filings/0001828318-26-000029.md) | [136](/filings/0001828318-26-000056.md) | [336](/filings/0001828318-25-000310.md) | [106](/filings/0001828318-26-000056.md) | [88.8](/filings/0001828318-26-000029.md) | [33.7](/filings/0001828318-26-000056.md) | | Current assets | $m | [376](/filings/0001828318-23-000206.md) | [323](/filings/0001828318-25-000057.md) | [278](/filings/0001828318-24-000066.md) | [270](/filings/0001628280-24-034500.md) | [224](/filings/0001828318-24-000233.md) | [295](/filings/0001828318-26-000006.md) | [270](/filings/0001828318-25-000148.md) | [228](/filings/0001828318-25-000275.md) | [589](/filings/0001828318-25-000310.md) | [542](/filings/0001828318-26-000056.md) | [558](/filings/0001828318-26-000029.md) | [506](/filings/0001828318-26-000056.md) | | Total assets | $m | [520](/filings/0001828318-23-000206.md) | [564](/filings/0001828318-25-000057.md) | [509](/filings/0001828318-24-000066.md) | [489](/filings/0001628280-24-034500.md) | [448](/filings/0001828318-24-000233.md) | [527](/filings/0001828318-26-000006.md) | [499](/filings/0001828318-25-000148.md) | [469](/filings/0001828318-25-000275.md) | [914](/filings/0001828318-25-000310.md) | [879](/filings/0001828318-26-000056.md) | [834](/filings/0001828318-26-000029.md) | [800](/filings/0001828318-26-000056.md) | | Current liabilities | $m | [44.1](/filings/0001828318-23-000206.md) | [61.0](/filings/0001828318-25-000057.md) | [56.9](/filings/0001828318-24-000066.md) | [67.9](/filings/0001628280-24-034500.md) | [59.5](/filings/0001828318-24-000233.md) | [53.7](/filings/0001828318-26-000006.md) | [57.8](/filings/0001828318-25-000148.md) | [52.3](/filings/0001828318-25-000275.md) | [60.6](/filings/0001828318-25-000310.md) | [65.0](/filings/0001828318-26-000056.md) | [50.9](/filings/0001828318-26-000029.md) | [52.1](/filings/0001828318-26-000056.md) | | Total liabilities | $m | [267](/filings/0001828318-23-000206.md) | [303](/filings/0001828318-25-000057.md) | [277](/filings/0001828318-24-000066.md) | [316](/filings/0001628280-24-034500.md) | [278](/filings/0001828318-24-000233.md) | [278](/filings/0001828318-26-000006.md) | [261](/filings/0001828318-25-000148.md) | [262](/filings/0001828318-25-000275.md) | [617](/filings/0001828318-25-000310.md) | [605](/filings/0001828318-26-000056.md) | [591](/filings/0001828318-26-000029.md) | [588](/filings/0001828318-26-000056.md) | | Long-term debt | $m | [167](/filings/0001828318-23-000206.md) | [169](/filings/0001828318-25-000057.md) | [168](/filings/0001828318-24-000066.md) | [169](/filings/0001628280-24-034500.md) | [169](/filings/0001828318-24-000233.md) | [170](/filings/0001828318-26-000006.md) | [169](/filings/0001828318-25-000148.md) | [169](/filings/0001828318-25-000275.md) | [518](/filings/0001828318-25-000310.md) | [519](/filings/0001828318-26-000056.md) | [520](/filings/0001828318-26-000029.md) | [521](/filings/0001828318-26-000056.md) | | Current portion of debt | $m | not reported | [1.6](/filings/0001828318-25-000057.md) | [1.6](/filings/0001828318-24-000066.md) | [1.6](/filings/0001628280-24-034500.md) | [0.2](/filings/0001828318-24-000233.md) | [0.2](/filings/0001828318-26-000006.md) | [0.2](/filings/0001828318-25-000148.md) | [0.2](/filings/0001828318-25-000275.md) | [0.2](/filings/0001828318-25-000310.md) | [0.2](/filings/0001828318-26-000056.md) | [0.2](/filings/0001828318-26-000029.md) | [0.2](/filings/0001828318-26-000056.md) | | Short-term borrowings | $m | not reported | [4.3](/filings/0001828318-24-000233.md) | [6.9](/filings/0001828318-24-000066.md) | [9.4](/filings/0001628280-24-034500.md) | [11.4](/filings/0001828318-24-000233.md) | [9.3](/filings/0001828318-25-000310.md) | [10.2](/filings/0001828318-25-000148.md) | [10.2](/filings/0001828318-25-000275.md) | [9.9](/filings/0001828318-25-000310.md) | [9.7](/filings/0001828318-26-000056.md) | [9.2](/filings/0001828318-26-000029.md) | [10.4](/filings/0001828318-26-000056.md) | | Shareholders' equity | $m | [252](/filings/0001828318-23-000206.md) | [258](/filings/0001828318-25-000057.md) | [229](/filings/0001828318-24-000066.md) | [170](/filings/0001628280-24-034500.md) | [168](/filings/0001828318-24-000233.md) | [247](/filings/0001828318-26-000006.md) | [235](/filings/0001828318-25-000148.md) | [204](/filings/0001828318-25-000275.md) | [294](/filings/0001828318-25-000310.md) | [271](/filings/0001828318-26-000056.md) | [241](/filings/0001828318-26-000029.md) | [210](/filings/0001828318-26-000056.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-28) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(28.2) d](/filings/0001828318-24-000233.md) | [(27.2) d](/filings/0001828318-26-000006.md) | [(35.0)](/filings/0001828318-25-000148.md) | [(26.9) d](/filings/0001828318-25-000275.md) | [(30.7) d](/filings/0001828318-25-000310.md) | [(16.0) d](/filings/0001828318-26-000006.md) | [(16.9)](/filings/0001828318-26-000029.md) | [(25.9) d](/filings/0001828318-26-000056.md) | [(25.5) d](/filings/0001828318-25-000310.md) | [(27.0) d](/filings/0001828318-26-000006.md) | [(33.1)](/filings/0001828318-26-000029.md) | [(21.8) d](/filings/0001828318-26-000056.md) | | Capital expenditure | $m | [17.3 d](/filings/0001828318-24-000233.md) | [28.8 d](/filings/0001828318-26-000006.md) | [15.1](/filings/0001828318-25-000148.md) | [25.2 d](/filings/0001828318-25-000275.md) | [19.5 d](/filings/0001828318-25-000310.md) | [16.4 d](/filings/0001828318-26-000006.md) | [6.3](/filings/0001828318-26-000029.md) | [8.0 d](/filings/0001828318-26-000056.md) | [3.0 d](/filings/0001828318-25-000310.md) | [1.0 d](/filings/0001828318-26-000006.md) | [3.2](/filings/0001828318-26-000029.md) | [9.6 d](/filings/0001828318-26-000056.md) | | Share repurchases | $m | [0.0 d](/filings/0001828318-24-000233.md) | [(0.0) d](/filings/0001828318-26-000006.md) | [0.0](/filings/0001828318-24-000066.md) | [0.0 d](/filings/0001828318-25-000275.md) | [(0.0) d](/filings/0001828318-25-000310.md) | [0.0 d](/filings/0001828318-26-000006.md) | not reported | not reported | [58.4 d](/filings/0001828318-25-000310.md) | [0.0 d](/filings/0001828318-26-000006.md) | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-10-02) | Q1 FY2023 (2023-04-02) | Q2 FY2023 (2023-07-02) | Q3 FY2023 (2023-10-01) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [153](/filings/0001828318-23-000206.md) | [156](/filings/0001828318-24-000066.md) | [157](/filings/0001628280-24-034500.md) | [161](/filings/0001828318-24-000233.md) | [168](/filings/0001828318-25-000148.md) | [183](/filings/0001828318-25-000275.md) | [188](/filings/0001828318-25-000310.md) | [203](/filings/0001828318-26-000029.md) | [205](/filings/0001828318-26-000056.md) | [207](/filings/0001828318-25-000310.md) | [217](/filings/0001828318-26-000029.md) | [219](/filings/0001828318-26-000056.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 219,448,535 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001828318-26-000056.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.